Inside Sarepta's Beat And Raise Q2

Sarepta Therapeutics Inc SRPT shares jumped up over 17 percent during Wednesday’s after-hours trading sessions, after the medical research and drug development company crushed earnings estimates.

A Closer Look At Q2 Earnings

  • Revenue: $35 million (consensus estimate was $22.3 million)
  • Adjusted Losses: $0.46 per share (was $1.19 per share last year)
  • Guidance: Raised to $125 million–$130 million (was $95 million)

After Nomura managing director Christopher Marai spoke to new CEO Doug Ingram following the earnings call, he also highlighted a positive view on Sarepta’s future similar to Ingram’s March 1 invitation theses. Marai maintains his Buy rating and set an $84 price target.

According to TipRanks, eight analysts are averaging a strong buy rating and a price target of $66 on Sarepta. Shares of Sarepta were trading at $40.20 during Thursday’s pre-market session, and at time of publication, shares were up 21.01 percent at $41.24.

To read the latest and exclusive financial news, visit the Benzinga Pro news wire.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: Analyst ColorBiotechEarningsLong IdeasNewsGuidancePrice TargetReiterationAnalyst RatingsMoversTrading IdeasGeneralChristopher MaraiDoug IngramNomura
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!